Advances in Non-Hodgkin lymphoma

Non-Hodgkin lymphoma (NHL), also known as non-Hodgkin's lymphoma, is a group of blood cancers that includes all types of lymphomas except Hodgkin lymphomas. Symptoms include enlarged lymph nodes, fever, night sweats, weight loss, and tiredness. Other symptoms may include bone pain, chest pain, or itchiness. Some forms are slow-growing while others are fast-growing. Unlike Hodgkin lymphoma, which spreads contiguously, NHL is largely a systemic illness.

In the present book, twelve typical literatures about Non-Hodgkin lymphoma published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on Non-Hodgkin lymphoma. We hope this book can demonstrate advances in Non-Hodgkin lymphoma as well as give references to the researchers, students and other related people.

Sample Chapter(s)
Preface (177 KB)
Components of the Book:
  • Chapter 1
    Intraocular manifestation of a diffuse large B-cell non-Hodgkin lymphoma of the pancreas
  • Chapter 2
    Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial
  • Chapter 3
    CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin’s lymphoma and tumor-supportive follicular T helper cells
  • Chapter 4
    Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
  • Chapter 5
    Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial
  • Chapter 6
    Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin’s lymphoma: a monocenter analysis
  • Chapter 7
    Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
  • Chapter 8
    Infections and their prognostic significance before diagnosis of chronic lymphocytic leukemia, non-Hodgkin lymphoma, or multiple myeloma
  • Chapter 9
    MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation
  • Chapter 10
    Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study
  • Chapter 11
    Solar ultraviolet radiation exposure, and incidence of childhood acute lymphocytic leukaemia and non-Hodgkin lymphoma in a US population-based dataset
  • Chapter 12
    Expression of L-type amino acid transporter 1 is a poor prognostic factor for Non-Hodgkin’s lymphoma
Readership: Students, academics, teachers and other people attending or interested in Non-Hodgkin lymphoma.
Mark P. Little
Faculty of Health and Life Sciences, Oxford Brookes University, Headington Campus, Oxford, OX3 0BP, UK

Pavel Chernyavskiy
Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, 22908-0717, USA

Victoria Kennerley
Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, 20892-9778, USA

and more...
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top